

## **BENLYSTA®**

## Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)

Name:	PATIENT INFORMATION (Complete or Fax Existing Chart)		PRESCRIBER INFORMATION	PRESCRIBER INFORMATION	
Primary Insurance:	Address:		_ State License: Tax _ NPI #: Tax _ Address: Tax _ City, State, Zip: _ Phone:	ID: Fax:	
Plan #:	INSURANCE INFORMATION – OR – Send a copy of the patient's prescription/insurance cards (front & back)				
M32.0 Drug-induced Systemic Lupus M32.1 Systemic Lupus Erythematosus (organ or system M32.9 Systemic Lupus Erythematosus, unspecified   L93.0 - Lupus Erythematosus (discoid) (NOS) Other:	Plan #: Group #: RX Card (PBM):		Plan #: Group #: RX Card (PBM):		
Erythematosus involvement) unspecified   L93.0 - Lupus Erythematosus (discoid) (NOS) Other:	CLINICAL INFORMATION				
Prescription type: New start Restart Continued therapy Total Doses Received: Date of Last Injection/Infusion:   Medication Directions Quantity/Refills   Benlysta® (belimumab) 10mg/KG at 0, 2 and 4 weeks; then every 4 weeks Quantity:   mg IV at 0, 2 and 4 weeks; then every 4 weeks Quantity:   Other: Refills:   SIGNATURE    We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.   X	Erythematosus     involvement)     unspecified          □ L93.0 - Lupus Erythematosus (discoid) (NOS)        □ Other:		nspecified		
Medication       Directions       Quantity/Refills         Image: Deline with the provide and the provide and the provide and the provide and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.       Image: Directions       Quantity/Refills         Medication       Image: Directions       Image: Directions       Image: Directions       Quantity/Refills         Image: Directions       Image: Directions       Image: Directions       Image: Directions       Image: Directions         Medication       SIGNATURE       Image: Directions       Image: Directions       Image: Directions         X       Date:       Directions       Image: Directions       Image: Directions	BENLYSTA® ORDERS				
Image: Description of the second	Prescription type:  New start Restar	t 🗌 Continued therapy Te	otal Doses Received: Date	e of Last Injection/Infusion:	
Benlysta® (belimumab)mg IV at 0, 2 and 4 weeks; then every 4 weeks   Other:    SIGNATURE  We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.     X   Date:	Medication	Directions		Quantity/Refills	
We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.         X       Date:	Benlysta® (belimumab)		2 and 4 weeks; then every 4 weeks		
medicine as prescribed in this referral.         X         Date:	SIGNATURE				
Prescriber Signature	X		Da	te:	

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.